Polypharmacological immune and inflammatory pathway targets

Polypharmacological immune and inflammatory pathway targets refer to a collective group of molecular entities—such as kinases, receptors, and cytokines—that are simultaneously modulated by a single therapeutic agent to treat complex inflammatory diseases (Hopkins, A. L., 2008, Nature Chemical Biology). This approach is particularly relevant in inflammatory disorders like rheumatoid arthritis and psoriasis, where redundant signaling pathways—such as the Janus kinase (JAK)/STAT and NF-κB cascades—drive pathology (Schett, G., et al., 2013, Nature Reviews Rheumatology). By modulating several nodes simultaneously, these therapies can achieve superior clinical outcomes compared to highly selective agents that may be bypassed by compensatory biological mechanisms. For instance, pan-JAK inhibitors like tofacitinib target multiple JAK isoforms to block the signaling of various pro-inflammatory cytokines (O'Shea, J. J., et al., 2013, New England Journal of Medicine). While effective, this strategy presents challenges in balancing therapeutic potency with the risk of systemic immunosuppression and off-target toxicities.

Other names

Multi-target immune pathwaysPolypharmacological network targetsMulti-target anti-inflammatory therapy

Simultaneous modulation of multiple distinct molecular targets within the immune and inflammatory signaling networks to achieve synergistic therapeutic effects and overcome pathway redundancy.